ब्लू जेट हेल्थकेयर लिमिटेड शेयर प्राइस

Q4FY26 और फुल ईयर परफॉर्मेंस और आउटलुक पर ब्लू जेट हेल्थकेयर मैनेजमेंट और एनालिस्ट के साथ कॉन्फ्रेंस कॉल. फुल अर्निंग ट्रांसक्रिप्ट सुनें.

• ट्रेंडलाइन
• 2 सप्ताह 1 दिन पहले

Pharmaceuticals company Blue Jet Healthcare announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Revenue from Operations: Stood at Rs 2,347 million in Q4FY26, compared to Rs 1,924 million in Q3FY26 (up 22% QoQ) and Rs 3,404 million in Q4FY25 (down 31.1% YoY). EBITDA: Stood at Rs 713 million (30% margin), compared to Rs 469 million (24% margin) in Q3FY26 (up 52% QoQ) and Rs 1,400 million (41% margin) in Q4FY25 (down 49.1% YoY). Profit After Tax (PAT): Stood at Rs 643 million (27% margin), compared to Rs 402 million (21% margin) in Q3FY26 (up 60% QoQ) and Rs 1,101 million (32% margin) in Q4FY25 (down 41.6% YoY). Gross Margin: Stood at 56.4% in Q4FY26, compared to 51.7% in Q3FY26 and 54.9% in Q4FY25. FY26 Financial Highlights: Revenue from Operations: Stood at Rs 9,473 million, compared to Rs 10,300 million in FY25 (down 8% YoY). EBITDA: Stood at Rs 2,941 million (31% margin), compared to Rs 3,777 million (37% margin) in FY25 (down 22.1% YoY). Profit After Tax (PAT): Stood at Rs 2,478 million (26% margin), compared to Rs 3,052 million (30% margin) in FY25 (down 18.8% YoY). Gross Margin: Stood at 54% in FY26, compared to 55.2% in FY25. Other Income: Increased to Rs 687 million in FY26 from Rs 463 million in FY25, primarily driven by foreign exchange gains. Business Highlights: Segment Performance: Contrast Media Intermediates: Contributed 52.50% to total revenue in FY26. The company supplies critical starting intermediates and advanced intermediates, holding relationships with 3 of the largest global manufacturers. Pharma Intermediates & APIs: Contributed 31.60% to total revenue in FY26. Performance in FY26 was impacted by lower sales, though the company noted that de-stocking and inventory normalization by customers is now complete. High Intensity Sweeteners: Contributed 13.90% to total revenue in FY26, serving over 300 customers globally. Strategic Updates: Projects: The ground-breaking ceremony for the Vizag project is completed, and project activities have commenced. Civil construction for the new R&D; centre in Hyderabad has started, with completion expected by September 2026. Commercial Wins: Received trial orders in Advanced Contrast Media from a new Japanese customer. Operational Focus: The company continues to focus on forward integration into more advanced intermediates for Contrast Media, operational efficiency, and maintaining long-standing customer relationships. Result PDF

• ट्रेंडलाइन
• 2 सप्ताह 1 दिन पहले

सुविधा मरीन डिस्चार्ज कनेक्टिविटी के साथ एडवांस्ड एफ्लूएंट ट्रीटमेंट प्लांट (ईटीपी) को एकीकृत करेगी और इसमें ज़ीरो लिक्विड डिस्चार्ज (ज़ेडएलडी) टेक्नोलॉजी शामिल होगी

• बिजनेस लाइन
• 3 महीने 1 सप्ताह पहले